BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 32923158)

  • 1. Repurposing CD8
    Gujar S; Pol JG; Kim Y; Kroemer G
    Oncoimmunology; 2020 Jul; 9(1):1794424. PubMed ID: 32923158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.
    Del Fresno C; García-Arriaza J; Martínez-Cano S; Heras-Murillo I; Jarit-Cabanillas A; Amores-Iniesta J; Brandi P; Dunphy G; Suay-Corredera C; Pricolo MR; Vicente N; López-Perrote A; Cabezudo S; González-Corpas A; Llorca O; Alegre-Cebollada J; Garaigorta U; Gastaminza P; Esteban M; Sancho D
    Front Immunol; 2021; 12():748103. PubMed ID: 34867974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection.
    Wang Z; Yang X; Zhong J; Zhou Y; Tang Z; Zhou H; He J; Mei X; Tang Y; Lin B; Chen Z; McCluskey J; Yang J; Corbett AJ; Ran P
    Nat Commun; 2021 Mar; 12(1):1724. PubMed ID: 33741972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The known unknowns of T cell immunity to COVID-19.
    Karlsson AC; Humbert M; Buggert M
    Sci Immunol; 2020 Nov; 5(53):. PubMed ID: 33208380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T Cell Memory: Understanding COVID-19.
    Jarjour NN; Masopust D; Jameson SC
    Immunity; 2021 Jan; 54(1):14-18. PubMed ID: 33406391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of IFNγ-Secreting CD4
    Matyushenko V; Isakova-Sivak I; Kudryavtsev I; Goshina A; Chistyakova A; Stepanova E; Prokopenko P; Sychev I; Rudenko L
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19: Significance of antibodies.
    Assadiasl S; Fatahi Y; Zavvar M; Nicknam MH
    Hum Antibodies; 2020; 28(4):287-297. PubMed ID: 32986664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1-Expressing SARS-CoV-2-Specific CD8
    Rha MS; Jeong HW; Ko JH; Choi SJ; Seo IH; Lee JS; Sa M; Kim AR; Joo EJ; Ahn JY; Kim JH; Song KH; Kim ES; Oh DH; Ahn MY; Choi HK; Jeon JH; Choi JP; Kim HB; Kim YK; Park SH; Choi WS; Choi JY; Peck KR; Shin EC
    Immunity; 2021 Jan; 54(1):44-52.e3. PubMed ID: 33338412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infection and Immune Memory: Variables in Robust Protection by Vaccines Against SARS-CoV-2.
    Ahluwalia P; Vaibhav K; Ahluwalia M; Mondal AK; Sahajpal N; Rojiani AM; Kolhe R
    Front Immunol; 2021; 12():660019. PubMed ID: 34046033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypes and Functions of SARS-CoV-2-Reactive T Cells.
    Jung MK; Shin EC
    Mol Cells; 2021 Jun; 44(6):401-407. PubMed ID: 34120892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells.
    Jung JH; Rha MS; Sa M; Choi HK; Jeon JH; Seok H; Park DW; Park SH; Jeong HW; Choi WS; Shin EC
    Nat Commun; 2021 Jun; 12(1):4043. PubMed ID: 34193870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Viral RNA Shedding for More Than 87 Days in an Individual With an Impaired CD8+ T Cell Response.
    Turner JS; Day A; Alsoussi WB; Liu Z; O'Halloran JA; Presti RM; Patterson BK; Whelan SPJ; Ellebedy AH; Mudd PA
    Front Immunol; 2020; 11():618402. PubMed ID: 33488630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunity against SARS-CoV-2: walking to the vaccination].
    Rodríguez Hernández C; Sanz Moreno L
    Rev Esp Quimioter; 2020 Dec; 33(6):392-398. PubMed ID: 32935536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
    Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
    Front Immunol; 2021; 12():658519. PubMed ID: 34276652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine-induced protection in aging adults and pandemic response.
    Schenkelberg T
    Biochem Biophys Res Commun; 2021 Jan; 538():218-220. PubMed ID: 33213845
    [No Abstract]   [Full Text] [Related]  

  • 18. CD8 T cell epitope generation toward the continually mutating SARS-CoV-2 spike protein in genetically diverse human population: Implications for disease control and prevention.
    Guo E; Guo H
    PLoS One; 2020; 15(12):e0239566. PubMed ID: 33301503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunity to glycan α-Gal and possibilities for the control of COVID-19.
    la Fuente J; Gortázar C; Cabezas-Cruz A
    Immunotherapy; 2021 Feb; 13(3):185-188. PubMed ID: 33307805
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-Term Existence of SARS-CoV-2 in COVID-19 Patients: Host Immunity, Viral Virulence, and Transmissibility.
    Wang X; Huang K; Jiang H; Hua L; Yu W; Ding D; Wang K; Li X; Zou Z; Jin M; Xu S
    Virol Sin; 2020 Dec; 35(6):793-802. PubMed ID: 33156486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.